This page is updated frequently with new Endometrial-related patent applications.
|Bcl6 expression in eutopic endometrium as a marker for endometriosis and subfertility|
Methods for identifying subjects as candidates for embryo implantation are provided. In some embodiments, the methods include providing a sample of endometrium isolated from a subject during the second half of the subject's menstrual cycle and determining whether the subject is a candidate based on the expression of bcl6 in the sample.
Greenville Health System
|Compositions and methods for modulating the immune system|
A novel class of embryo derived peptides are described (preimplantation factor) that were generated synthetically and were tested on peripheral blood immune cells and shown to block activated but not basal immunity, inhibiting cell proliferation and creating a th2 type cytokine bias, in addition pif enhance endometrial receptivity by increasing adhesion molecules expression. Pif biological activity appears to be exerted by specific binding to inducible receptors present on the several white cell lineages.
|Use of eribulin and mtor inhibitors as combination therapy for the treatment of cancer|
Methods for treating cancer (e.g., breast cancer, lung cancer, pancreatic cancer, primitive neuroectodermal tumors, lung cancer, ovarian cancer, endometrial cancer, pharyngeal cancer, esophageal cancer, and sarcoma) in a subject (such as an human patient) in need thereof by administering eribulin (e.g., eribulin mesylate, i.e., e7389, halaven) in combination with one or more mammalian target of rapamycin (mtor) inhibitors (e.g., everolimus, ridaforolimus, and temsirolimus), and kits therefor are provided.. .
Eisai R&d Management Co., Ltd.
|Systems and methods for endometrial ablation|
An endocervical seal has a sleeve with a passageway for receiving an intrauterine interventional or diagnostic tool. The sleeve has a coaxially disposed outer balloon with a distal portion configured to inflate in a cervical os and a proximal portion configured to inflate in a cervical canal..
Minerva Surgical, Inc.
|Antibodies, antibody drug conjugates and methods of use|
This invention relates to antibody drug conjugates (adc), antibody conjugates (ac) and novel antibodies. Particularly, the adc, ac and antibodies disclosed herein specifically bind to the human anti-müllerian hormone type ii receptor (amhr-ii) and can be used to treat and/or identify amhr-ii expressing cancers, such as prostate cancer, breast cancer and gynecologic cancers expressing amhr-ii, such as ovarian cancer, in particular metastatic ovarian cancer, serous cancer, hypernephroma, endometrioid, colloidal epithelium, prostate cancer, germ cell cancer, endometrial cancer, mixed müllerian malignant tumor of the uterus, leiomyosarcoma, or endometrial stromal sarcoma..
|Methods and systems for endometrial treatment|
Methods of treating endometrial dysfunction are described including retrieval of endometrial cells including endometrial stem cells from a fertile donor and transplantation of endometrial cells or tissue into a host suffering from endometrial dysfunction. In certain embodiments, methods include genetic modification, tissue culturing, or cryopreservation of the endometrial cells prior to transplantation.
|Duocarmycin adcs for use in treatment of endometrial cancer|
The present invention relates to duocarmycin-containing antibody-drug conjugates (adcs) for use in the treatment of human solid tumours expressing her2, wherein the human solid tumour expressing her2 is endometrial cancer, in particular uterine serous carcinoma (usc). In particular, the present invention relates to duocarmycin-containing adcs for use in the treatment of endometrial cancer, notably usc, with her2 ihc 2− or 1+ and her2 fish negative tumour tissue status..
|Methods for detecting, diagnosing and treating endometrial cancer|
The present invention relates to methods for detecting, diagnosing and/or treating endometrial cancer by detecting in a biological sample from a patient the levels of one or more of the metabolites: c14.2, pc ae c38:1, 3-hydroxybutyric acid, c18:2, pc ae c40:1, and c6 (c4:1-dc). In some embodiments, the method also includes diagnosing the patient with endometrial cancer when the one or more metabolites in the biological sample is at a different level than a statistically validated threshold for the one or more metabolites, and ultrasound indicates endometrial cancer in the patient.
William Beaumont Hospital
|Therapeutic immune modulation by stem cell secreted exosomes|
Disclosed are methods, compositions of matter, and protocols useful for the induction of a therapeutic immune modulatory response through administration of exosomes derived from a stem cell source. In one embodiment, said stem cell source is endometrial regenerative cells.
Xon Cells, Inc.
|Device for endometrial ablation having an expandable seal for a cervical canal|
Methods, systems and devices for endometrial ablation. In accordance with a method, a working end of an rf ablation device is positioned in a patient uterus to contact endometrial tissue, the working end comprising a dielectric wall capable of non-expanded and expanded shapes and for conforming to an asymmetric or symmetric shape of the patient's cervix.
Minerva Surgical, Inc.
Isolation, detection, diagnosis and/or characterization of circulating trop-2-positive cancer cells
Described herein are compositions and methods of use of anti-trop-2 antibodies or antigen-binding fragment thereof to isolate, enrich, detect, diagnose and/or characterize circulating tumor cells (ctcs) from patients with a trop-2 positive cancer. Preferably, the antibody is an rs7, 162-46.2 or mab650 antibody.
Detection of chromosomal abnormalities associated with endometrial cancer
The methods and compositions described herein address the need for diagnostic method that could be offered to women during yearly checkups to allow for early detection, diagnosis and classification, and treatment of endometrial cancer. In addition, these methods and compositions address the current need for improving diagnostic accuracy of biopsy procedures in symptomatic patients..
Aryl naphthyl methanone oxime(s) and process for preparation thereof
The present invention relates to substituted aryl naphthyl methanone oximes of general formula (i), their process for preparation and their derivatives, salts, pharmaceutical composition thereof and their use in treatment of chronic myelogenous leukemia, acute myelogenous leukemia, lymphoma, multiple myeloma, solid tumor forming cell- lines including such as breast cancer, endometrial cancer colon cancer, prostate cancer and killing of drug resistant cancer stem cells, as subject in need thereof.. .
Council Of Scientific & Industrial Research
Systems and methods for endometrial ablation
A device for endometrial ablation having an elongated shaft with a working end comprising an expandable-contractable frame, a complaint energy-delivery surface carried by the frame, the surface and the frame being configured to engage against the interior of a patient's uterine cavity when the working end is inserted into the cavity and the frame is expanded.. .
Minerva Surgical, Inc.
Method of evaluating female genital cancer
According to the method of evaluating female genital cancer of the present invention, amino acid concentration data on concentration values of amino acids in blood collected from a subject to be evaluated is measured, and the state of female genital cancer including at least one of cervical cancer, endometrial cancer, and ovarian cancer in the subject is evaluated based on the concentration value of at least one of thr, ser, asn, gln, pro, gly, ala, cit, val, met, ile, leu, tyr, phe, his, trp, orn, lys, and arg contained in the measured amino acid concentration data of the subject.. .
Ajinomoto Co., Inc.
Method of treating endometrial tissue disease by altering an epithelial to mesenchymal transition
The present invention is a method of treating endometrial tissue disease and in particular a method of treating endometriosis and adenomyosis by administering an epithelial-to-mesenchymal transition altering compound. The compound may be a natural compound or a synthetic compound.
Preventing or mitigating chemotherapy induced alopecia using vitamin d
The invention provides methods and pharmaceutical compositions for preventing or mitigating chemotherapy-induced alopecia (cia). The pharmaceutical compositions of the invention comprise an effective amount of a vitamin d compound in a topical formulation.
System and endometrial ablation
A wall of a uterus is ablated by expanding a structure in the uterus and applying energy across the wall of the structure into the uterine wall. An exterior surface of the structure conforms to an inner wall of the uterus, and the energy may cause vapor to collect between the wall and the structure.
Minerva Surgical, Inc.
Methods of diagnosing, classifying and treating endometrial cancer and precancer
Diagnostic and therapeutic applications for endometrial cancer are described. The diagnostic and therapeutic applications are based on certain activation mutations in the fgfr2 gene and its expression products.
Substituted 1,2,3,4-tetrahydroisoquinoline derivatives for the treatment of hormone-dependent diseases
Provided are compounds of general formula a and a′, wherein x1 and x2 are each c, ch or n; r3 and r4 are each h, optionally substituted c1-c30 saturated or unsaturated chemical group, or together form an optionally substituted c5-c8 cycle; z1; z2 and z3 are each n or ch; v is c═o, c═s or ch2; n is from 1 to 12; w1 and w2 are each h, ch2, o or s; and r1 and r2 are each h, cr1c6 alkyl, c1c6 aryl, c1c12 alkylaryl, optionally substituted phenyl, c1c6 alkoxy, c1c6 thioalkoxy, f, cl, br or i. These compounds inhibit steroid sulfatase (sts), act as selective estrogen receptor modulators (serms), increase alkaline phosphatase (alp) activity, and are useful in the treatment of medical conditions involving hormones such as breast cancer, prostate cancer, endometriosis, osteoporosis, benign prostatic hyperplasia and endometrial cancer..
Methods and systems for endometrial ablation utilizing radio frequency
Methods, systems and devices for endometrial ablation. In accordance with a method, a working end of an rf ablation device is positioned in a patient uterus to contact endometrial tissue, the working end comprising a dielectric wall capable of non-expanded and expanded shapes.
Minerva Surgical, Inc.
Endometrial sample collector
A non-invasive endometrial sample collector has an outer body of absorbent material configured for insertion into a vaginal cavity of a patient such that a distal end of the body is positioned proximate a uterine cervix of the patient. The collector has an internal collection assembly disposed within the outer body of absorbent material.
Method for separation of sporadic cells from body fluids, and carrying out said method
Method for gentle separation of viable sporadic cells from body fluids such as blood, from malignant effusions, bronchoalveolar lavage fluid, peritoneal lavage fluid and amniotic fluid, based on a filter membrane which is in an intimate contact with an absorbent material. Using the present method it is possible to isolate for example circulating and disseminated tumor cells, endometrial cells and circulating trophoblast cells, allowing subsequent detection, quantification, characterization and especially culturing of said cells.
Prevention, treatment, and amelioration of radiation induced enteritis
The present invention provides a new method of ameliorating and/or treating enteritis induced by radiation therapy, alone or in combination with other therapies, for the treatment oil for example, gastrointestinal malignancies, including colorectal, appendiceal, anal, or small bowel cancers; urogenital malignancies, including prostate, bladder, testicular, or penile cancers; gynecologic malignancies, including cervical, endometrial, ovarian, vaginal, or vulvar cancers; or osteogenic and other sarcomatous malignancies in which pelvic structures are involved, comprising the administration of a therapeutically effective amount of balsalazide to a patient in need thereof. .
Endometrial lining tissue treatment device
An endometrial tissue treatment device includes an elongate positioning member and an energy applicator coupled to a distal end of the positioning member, the energy applicator including a tissue contacting member and an expandable-collapsible support structure underlying the tissue contacting member, the expandable-collapsible support structure comprising a substantially non-compliant elongate balloon disposed within the tissue contacting member that, when inflated, has a length oriented substantially transverse to the positioning member, including a first closed end that positions a corresponding first corner portion of the tissue contacting member in a first cornu of a uterine cavity, and a second closed end that positions a corresponding second corner portion of the tissue contacting member in a second cornu of a uterine cavity, with a lengthwise portion of the balloon positioning a distal facing portion of the tissue contacting member for contacting a fundal wall of a uterus.. .
Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds
Biomarkers are provided that predict whether a subject having endometrial cancer will or will not respond to a therapy comprising lenvatinib or a pharmaceutically acceptable salt thereof (e.g., lenvatinib mesylate). The biomarkers, compositions, and methods described herein are useful in selecting appropriate treatment modalities for and treating a subject having, suspected of having, or at risk of developing an endometrial cancer..
Eisai R&d Management Co., Ltd.
Asrgl1 in endometrial cancer
There is provided a method for determining whether a mammalian subject having an endometrial cancer belongs to a first or a second group, wherein the prognosis of subjects of the first group is better than the prognosis of subjects of the second group, comprising the steps of: a) evaluating an amount of asrgl1 in at least part of a sample earlier obtained from the subject and determining a sample value corresponding to the evaluated amount; b) comparing said sample value with a predetermined reference value; and if said sample value is higher than said reference value, c1) concluding that the subject belongs to the first group; and if said sample value is lower than or equal to said reference value, c2) concluding that the subject belongs to the second group.. .
Atlas Antibodies Ab
Ras inhibitors and uses thereof
Described herein are compounds of formulae (i)-(ii), and pharmaceutically acceptable salts, and pharmaceutical compositions thereof. Also provided are methods and kits involving the inventive compounds or compositions for treating or preventing proliferative diseases such as cancers (e.g., lung cancer, large bowel cancer, pancreas cancer, biliary tract cancer, or endometrial cancer), benign neoplasms, angiogenesis, inflammatory diseases, autoinflammatory diseases, and autoimmune diseases in a subject..
Dana-farber Cancer Institute, Inc.
Msi-specific frameshift peptides (fsp) for prevention and treatment of cancer
Described is a vaccine for prevention and treatment of cancer characterized by microsatellite instability (msi). The vaccine contains an msi-specific frameshift peptide (fsp) generating humoral and cellular responses against tumor cells or a nucleic acid encoding said fsp.
Treatment of endometriosis, angiogenesis and/or endometrial lesion growth
Synuclein-gamma (sncg) inhibitors are useful for inhibiting or treating angiogenesis, endometriosis and/or endometrial lesion growth. They also potentiate efficacy of other hormonal agents in treating angiogenesis, endometriosis and/or endometrial lesion growth..
Syng Pharmaceuticals Inc.
Methods of diagnosing endometriosis
The present invention provides biomarkers for the diagnosis and prognosis of endometriosis. Generally, the methods of this invention find use in diagnosing or for providing a prognosis for endometriosis by detecting the expression levels of biomarkers, which are differentially expressed (up- or down-regulated) in endometrial cells from a patient with endometriosis.
The Regents Of The University Of California
Follow us on Twitter
This listing is a sample listing of patent applications related to Endometrial for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Endometrial with additional patents listed. Browse our RSS directory or Search for other possible listings.